SlideShare a Scribd company logo
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 1
Severe Acute Respiratory Syndrome (SARS):
Global Alert, Global Response
World Health Organization
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 2
Electronic
Discussion sites
Media
NGOs
Military
Laboratory
Networks
WHO Collaborating
Centres/Laboratories Epidemiology and
Surveillance Networks
WHO Regional
& Country Offices
Countries/National
Disease Control
Centres
UN
Sister Agencies
FORMAL
GPHIN
Partnership for global alert and response to
infectious diseases: network of networks
INFORMAL
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 3
Surveillance network partners in Asia
Mekong
Basin
Disease
Surveillance
(MBDS)
Pacific Public Health
Surveillance Network
(PPHSN)
ASEAN
APEC
SEAMIC
SEANET
EIDIOR
FluNet
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 4
Global Public Health Intelligence
Network, Canada
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 5
FluNet: Global surveillance of human
influenza: Participating laboratories, 2003
1 laboratory > 1 laboratory national network
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 6
Reports of respiratory infection, WHO global
surveillance networks, 2002–2003
 27 November
– Guangdong Province, China: Non-official report of outbreak of respiratory illness with
government recommending isolation of anyone with symptoms (GPHIN)
 11 February
– Guangdong Province, China: report to WHO office Beijing of outbreak of atypical
pneumonia (WHO)
 14 February
– Guangdong Province, China: Official confirmation of an outbreak of atypical pneumonia
with 305 cases and 5 deaths (China)
 19 February
– Hong Kong, SAR China: Official report of 33-year male and 9 year old son in Hong Kong
with Avian influenza (H5N1), source linked to Fujian Province, China (Hong Kong, FluNet)
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 7
Intensified surveillance for pulmonary
infections, WHO 2003
 26 February
– Hanoi, Viet Nam: Official report of 48-year-old business man with high fever (> 38 ºC),
atypical pneumonia and respiratory failure with history of previous travel to China and
Hong Kong
 5 March
– Hanoi, Viet Nam: Official report of 7 medical staff from French Hospital reported with
atypical pneumonia
 Early March
– Hong Kong, SAR China Official report of 77 medical staff from Hospital reported with
atypical pneumonia`, WHO teams arrive Hong Kong and Hanoi, and with governments
advise on investigation and containment activities
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 8
Global Alert:
Severe Acute Respiratory Syndrome (SARS)
 12 March: First global alert
– describing atypical pneumonia in Viet Nam and Hong Kong
 14 March
– Four persons Ontario, three persons in Singapore, with severe atypical pneumonia fitting
description of 12 March alert reported to WHO
 15 March
– Medical doctor with atypical pneumonia fitting description of 12 March reported by
Ministry of Health, Singapore on return flight from New York
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 9
Global Alert, 15 March 2003
1) Atypical pneumonia with rapid progression to respiratory failure
2) Health workers appeared to be at greatest risk
3) Unidentified cause, presumed to be an infectious agent
4) Antibiotics and antivirals did not appear effective
5) Spreading internationally within Asia and to Europe and
North America
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 10
 15 March: Second global alert
• Case definition provided
• Name (SARS) announced
• Advice given to international travellers to raise awareness
 26 March
Evidence accumulating that persons with SARS continued to travel from areas with
local transmission, and that adjacent passengers were at small, but non-quantified risk
 27 March
Guidance provided to airlines and areas with local transmission to screen passengers
leaving in order to decrease risk of international travel by persons with SARS
Global Alert:
Severe Acute Respiratory Syndrome (SARS)
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 11
Global Alert:
Severe Acute Respiratory Syndrome (SARS)
 1 April:
Evidence accumulating from exported cases that three criteria were potentially
increasing international spread:
– magnitude of outbreak and number of new cases each day
– pattern of local transmission
– exportation of probable cases
 2 April to present:
Guidance provided to general public to postpone non-essential travel to areas
with local transmission that met above criteria
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 12
SARS: cumulative number of probable cases
worldwide as of 12 June 2003 – Total: 8 445 cases, 790
deaths
China (5328)
Singapore (206)
Hong Kong (1755)
Viet Nam (63)
Europe:
10 countries (38)
Thailand (9)
Brazil (3)
Malaysia (5)
South Africa (1)
Canada (238)
USA (70)
Outbreaks before 15 March global alert
Colombia (1)
Kuwait (1)
South Africa (1)
Korea Rep. (3)
Macao (1)
Philippines (14)
Indonesia (2)
Mongolia (9)
India (3)
Australia (5)
New Zealand (1)
Taiwan (688)
Outbreaks after 15 March global alert
Mongolia (9)
Russian Fed. (1)
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 13
Probable cases of SARS by date of onset,
Hanoi: n = 62
1 February – 12 June 2003
0
1
2
3
4
5
6
7
8
9
10
1 Feb. 11 Feb. 21 Feb. 3 March 13 March 23 March 2 April 12 April 22 April 2 May 12 June
Number
of
cases
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 14
Probable cases of SARS by date of onset,
Singapore: n = 206
1 February – 12 June 2003
Source: Ministry of
Health, Singapore, WHO
0
2
4
6
8
10
12
14
1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 29 May
Number
of
cases
12 Jun.
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 15
Probable cases of SARS by date of onset,
Canada: n = 227*
1 February – 12 June 2003
Number
of
cases
0
1
2
3
4
5
6
7
8
9
10
1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 -Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 1 Jun. 12 Jun.
* As of 12 June 2003, 11
additional probable cases
of SARS have been reported
from Canada for whom no dates
of onset are available.
Source: Health Canada
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 16
Probable cases of SARS by date of onset,
Taiwan: n = 688
1 February – 12 June 2003
Number
of
cases
0
5
10
15
20
25
30
1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 1 Jun. 12 Jun.
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 17
Probable cases of SARS by date of onset,
Beijing: n = 2,522
0
50
100
150
200
250
300
350
30-Mar-03 13-Apr-03 27-Apr-03 11-May-03 25-May-03 8-Jun-03
date of report
number
of
cases
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 18
156 close
contacts
of HCW
and
patients
Index case
from
Guangdong
Hospital 2
Hong Kong
4 HCW +
2
Hospital 3
Hong Kong
3 HCW
Hospital 1
Hong Kong
99 HCW
Canada
12 HCW +
4
Hotel M
Hong Kong
Ireland
USA
New York
Singapore
34 HCW +
37
Viet Nam
37 HCW +
?
Bangkok
HCW
4 other
Hong Kong
hospitals
28 HCW
Hospital 4
Hong Kong
B
I
K
F G
E
D
C
J
H
A
SARS: chain of transmission among guests
at Hotel Metropole, Hong Kong, 21 February
Germany
HCW +
2
As of 26
March,
249 cases
have been
traced to
the A case
Source: WHO/CDC
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 19
Airport screening and health information, Hong
Kong, SARS, 2003
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 20
Probable cases of SARS by date of onset,
Hong Kong: n = 1 753, as of 9 June 2003
Number
of
cases
0
1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 1 Jun. 9 Jun.
0
20
40
60
80
100
120
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 21
SARS and the economy:
impact on global travel, Hong Kong
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 22
SARS and the economy:
impact on global travel, Singapore
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 23
The cost of SARS: Initial estimates, Asian
Development Bank
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 24
1) Atypical pneumonia with rapid progression to respiratory failure:
– Case fatality rate by age group:
– 85% full recovery
– Incubation period: 3–10 days
2) Health workers appeared to be at greatest risk
– Health workers remain primary risk group in second generation
– Others at risk include family members of index cases and health workers, and their
contacts
– Majority of transmission has been close personal contact; in Hong Kong environmental
factors caused localized transmission
< 1% < 24 years old
6% 25–44 years old
15% 45–64 years old
> 50% > 65 years old
SARS: what more we know
3 months later
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 25
SARS: what more we know
3 months later
3) Unidentified cause, presumed to be an infectious agents
– Aetiological agent: Coronavirus, hypothesized to be of animal origin
– PCR and various antibody tests developed and being used in epidemiological studies,
but PCR lacks sufficient sensitivity as diagnostic tool
4) Antibiotics and antivirals did not appear effective
– Studies under way to definitively provide information on effectiveness of antivirals
alone or in combination with steroids, and on use of hyperimmune serum in persons
with severe disease
– Case detection, isolation, infection control and contact tracing are effective means of
containing outbreaks
– Meeting 30 April at NIH to examine priorities in drugs and vaccine developments
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 26
SARS: what more we know
3 months later
5) Spreading internationally within Asia and to Europe and North America
– Only 1 major outbreak occurred after 15 March despite initial exported cases to a
total of 32 countries
– Symptomatic persons with SARS no longer travelling internationally
– International spread occurring the in small number of persons who are in
incubation period
– Since 15 March, 27 persons on 4 of 32 international flights carrying symptomatic
persons with SARS appear to have been infected (1 flight alone on 15 March has
accounted for 22 of these 27 cases), and these occurred before 23 March
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 27
SARS:
what we are learning
 In the world today an infectious disease in one country is a threat to all: infectious diseases
do not respect international borders
 Information and travel guidance can contain the international spread of an infectious
disease
 Experts in laboratory, epidemiology and patient care can work together for the public health
good despite heavy pressure to publish academically
 Emerging infectious disease outbreaks often have an unnecessary negative economic
impact on tourism, travel and trade
 Infectious disease outbreaks reveal weaknesses in public health infrastructure
 Emerging infections can be contained with high level government commitment and
international collaboration if necessary
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 28
SARS: what Hong Kong has contributed
to the global effort
 Reporting: open and transparent reporting of H5N1 on 19 February that led to intensified
global surveillance for respiratory disease
 Reporting: open and transparent reporting in early March of health worker infection, leading
to global alert on 12 March
 Information: new cases and deaths reported regularly to WHO
 Science: coronavirus first isolated and identified, early PCR and antibody tests developed,
environmental factors involved in transmission identified, studies on animal reservoir in
collaboration with Guandong scientists conducted
 Outbreak Control: prompt reaction once outbreak had been identified, with effective case
identification, contact tracing, isolation/infection control, surveillance and quarantine despite
environmental transmission at Amoy Gardens
 Patient management: controlled studies on antivrial drugs alone and in combination with
steroids, convalescent serum for treatment
WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 29
SARS: what Hong Kong will contribute
to the global effort over coming months
 Continued case identification through surveillance:
– necessary to determine whether infection is endemic and seasonal, or
whether it has disappeared from human populations
 Continued collaboration with China, particularly Guangdong Province in
studies to identify animal reservoir and risk factors for transmission to
humans
– necessary to manage the risk and prevent future outbreaks
 Continued participation in major WHO networks of global surveillance for
influenza and other infectious diseases
– identify next major emergence of new influenza strain or other infection of
international importance

More Related Content

Similar to WHO_SARS_GLOBAL RESPONSE.ppt

Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.Jean Jacques Bernatas
 
Forecasting the peak and fading out of novel coronavirus of 2019
Forecasting the peak and fading out of novel coronavirus of 2019Forecasting the peak and fading out of novel coronavirus of 2019
Forecasting the peak and fading out of novel coronavirus of 2019Islam Saeed
 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014Ashraf ElAdawy
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseasesSASMITANAYAK28
 
Travel related infectious disease 2.pptx
Travel related infectious disease 2.pptxTravel related infectious disease 2.pptx
Travel related infectious disease 2.pptxGovindRankawat1
 
update51_pandemic_overview_where_are_we_now (1).pptx
update51_pandemic_overview_where_are_we_now (1).pptxupdate51_pandemic_overview_where_are_we_now (1).pptx
update51_pandemic_overview_where_are_we_now (1).pptxKakashiGanz
 
COVID 19 meta analysis - DIG- April-28-2020
COVID 19 meta analysis - DIG- April-28-2020COVID 19 meta analysis - DIG- April-28-2020
COVID 19 meta analysis - DIG- April-28-2020Andrew MacPherson
 
Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...
Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...
Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...Flávio Codeço Coelho
 
Abstract congress covid 19.docx30
Abstract congress covid 19.docx30Abstract congress covid 19.docx30
Abstract congress covid 19.docx30Enida Xhaferi
 
Corona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULYCorona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULYNARENDRA MALHOTRA
 
Presentation on COVID-19 in March 2020
Presentation on COVID-19 in March 2020Presentation on COVID-19 in March 2020
Presentation on COVID-19 in March 2020Tehmas Ahmad
 
Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...Valentina Corona
 

Similar to WHO_SARS_GLOBAL RESPONSE.ppt (20)

Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.
 
Coronavirus Pandemic
Coronavirus PandemicCoronavirus Pandemic
Coronavirus Pandemic
 
Dethroning CORONA virus
Dethroning CORONA virusDethroning CORONA virus
Dethroning CORONA virus
 
EpiBrief_2_2014
EpiBrief_2_2014EpiBrief_2_2014
EpiBrief_2_2014
 
Forecasting the peak and fading out of novel coronavirus of 2019
Forecasting the peak and fading out of novel coronavirus of 2019Forecasting the peak and fading out of novel coronavirus of 2019
Forecasting the peak and fading out of novel coronavirus of 2019
 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
 
Travel related infectious disease 2.pptx
Travel related infectious disease 2.pptxTravel related infectious disease 2.pptx
Travel related infectious disease 2.pptx
 
update51_pandemic_overview_where_are_we_now (1).pptx
update51_pandemic_overview_where_are_we_now (1).pptxupdate51_pandemic_overview_where_are_we_now (1).pptx
update51_pandemic_overview_where_are_we_now (1).pptx
 
COVID 19 meta analysis - DIG- April-28-2020
COVID 19 meta analysis - DIG- April-28-2020COVID 19 meta analysis - DIG- April-28-2020
COVID 19 meta analysis - DIG- April-28-2020
 
Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...
Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...
Carl koppeschaar: Disease Radar: Measuring and Forecasting the Spread of Infe...
 
CME Monkey POX Dr S dave.pptx
CME Monkey POX Dr S dave.pptxCME Monkey POX Dr S dave.pptx
CME Monkey POX Dr S dave.pptx
 
Lakshita10 a
Lakshita10 aLakshita10 a
Lakshita10 a
 
Abstract congress covid 19.docx30
Abstract congress covid 19.docx30Abstract congress covid 19.docx30
Abstract congress covid 19.docx30
 
Corona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULYCorona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULY
 
SARS epidemiolody and morphology of the virus
SARS epidemiolody and morphology of the virusSARS epidemiolody and morphology of the virus
SARS epidemiolody and morphology of the virus
 
Presentation on COVID-19 in March 2020
Presentation on COVID-19 in March 2020Presentation on COVID-19 in March 2020
Presentation on COVID-19 in March 2020
 
Document copia
Document   copiaDocument   copia
Document copia
 
Document
DocumentDocument
Document
 
Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...
 

More from Avinash Kavi

Basic First Aid for Students - Dr. A. Kavi.pptx
Basic First Aid for Students - Dr. A. Kavi.pptxBasic First Aid for Students - Dr. A. Kavi.pptx
Basic First Aid for Students - Dr. A. Kavi.pptxAvinash Kavi
 
Basic First Aid for Students - Dr. Avinash Kavi
Basic First Aid for Students - Dr. Avinash KaviBasic First Aid for Students - Dr. Avinash Kavi
Basic First Aid for Students - Dr. Avinash KaviAvinash Kavi
 
Respiratory_Tract_Infections.ppt
Respiratory_Tract_Infections.pptRespiratory_Tract_Infections.ppt
Respiratory_Tract_Infections.pptAvinash Kavi
 
Community Based Rehabilitation.ppt
Community Based Rehabilitation.pptCommunity Based Rehabilitation.ppt
Community Based Rehabilitation.pptAvinash Kavi
 
Disease prevention & control.ppt
Disease prevention & control.pptDisease prevention & control.ppt
Disease prevention & control.pptAvinash Kavi
 
DISABILITY & ITS INDICATORS.pptx
DISABILITY & ITS INDICATORS.pptxDISABILITY & ITS INDICATORS.pptx
DISABILITY & ITS INDICATORS.pptxAvinash Kavi
 
Nutritional Assessment of the Community - Dr. A. Kavi.pptx
Nutritional Assessment of the Community - Dr. A. Kavi.pptxNutritional Assessment of the Community - Dr. A. Kavi.pptx
Nutritional Assessment of the Community - Dr. A. Kavi.pptxAvinash Kavi
 

More from Avinash Kavi (7)

Basic First Aid for Students - Dr. A. Kavi.pptx
Basic First Aid for Students - Dr. A. Kavi.pptxBasic First Aid for Students - Dr. A. Kavi.pptx
Basic First Aid for Students - Dr. A. Kavi.pptx
 
Basic First Aid for Students - Dr. Avinash Kavi
Basic First Aid for Students - Dr. Avinash KaviBasic First Aid for Students - Dr. Avinash Kavi
Basic First Aid for Students - Dr. Avinash Kavi
 
Respiratory_Tract_Infections.ppt
Respiratory_Tract_Infections.pptRespiratory_Tract_Infections.ppt
Respiratory_Tract_Infections.ppt
 
Community Based Rehabilitation.ppt
Community Based Rehabilitation.pptCommunity Based Rehabilitation.ppt
Community Based Rehabilitation.ppt
 
Disease prevention & control.ppt
Disease prevention & control.pptDisease prevention & control.ppt
Disease prevention & control.ppt
 
DISABILITY & ITS INDICATORS.pptx
DISABILITY & ITS INDICATORS.pptxDISABILITY & ITS INDICATORS.pptx
DISABILITY & ITS INDICATORS.pptx
 
Nutritional Assessment of the Community - Dr. A. Kavi.pptx
Nutritional Assessment of the Community - Dr. A. Kavi.pptxNutritional Assessment of the Community - Dr. A. Kavi.pptx
Nutritional Assessment of the Community - Dr. A. Kavi.pptx
 

Recently uploaded

Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCatherine Liao
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxDr KHALID B.M
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyDr KHALID B.M
 
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...kevinkariuki227
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...kevinkariuki227
 
US E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complexUS E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complexClive Bates
 
Mastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial FreedomMastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial FreedomFatimaMary4
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Dr. Aryan (Anish Dhakal)
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...Catherine Liao
 
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Catherine Liao
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Catherine Liao
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfDr Jeenal Mistry
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Catherine Liao
 
5cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +852975043415cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +85297504341Sherrylee83
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxdrwaque
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxgauripg8
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsLanceCatedral
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...KavyasriPuttamreddy
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...Catherine Liao
 

Recently uploaded (20)

Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
 
US E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complexUS E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complex
 
Mastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial FreedomMastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial Freedom
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
 
5cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +852975043415cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +85297504341
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 

WHO_SARS_GLOBAL RESPONSE.ppt

  • 1. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 1 Severe Acute Respiratory Syndrome (SARS): Global Alert, Global Response World Health Organization
  • 2. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 2 Electronic Discussion sites Media NGOs Military Laboratory Networks WHO Collaborating Centres/Laboratories Epidemiology and Surveillance Networks WHO Regional & Country Offices Countries/National Disease Control Centres UN Sister Agencies FORMAL GPHIN Partnership for global alert and response to infectious diseases: network of networks INFORMAL
  • 3. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 3 Surveillance network partners in Asia Mekong Basin Disease Surveillance (MBDS) Pacific Public Health Surveillance Network (PPHSN) ASEAN APEC SEAMIC SEANET EIDIOR FluNet
  • 4. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 4 Global Public Health Intelligence Network, Canada
  • 5. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 5 FluNet: Global surveillance of human influenza: Participating laboratories, 2003 1 laboratory > 1 laboratory national network
  • 6. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 6 Reports of respiratory infection, WHO global surveillance networks, 2002–2003  27 November – Guangdong Province, China: Non-official report of outbreak of respiratory illness with government recommending isolation of anyone with symptoms (GPHIN)  11 February – Guangdong Province, China: report to WHO office Beijing of outbreak of atypical pneumonia (WHO)  14 February – Guangdong Province, China: Official confirmation of an outbreak of atypical pneumonia with 305 cases and 5 deaths (China)  19 February – Hong Kong, SAR China: Official report of 33-year male and 9 year old son in Hong Kong with Avian influenza (H5N1), source linked to Fujian Province, China (Hong Kong, FluNet)
  • 7. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 7 Intensified surveillance for pulmonary infections, WHO 2003  26 February – Hanoi, Viet Nam: Official report of 48-year-old business man with high fever (> 38 ºC), atypical pneumonia and respiratory failure with history of previous travel to China and Hong Kong  5 March – Hanoi, Viet Nam: Official report of 7 medical staff from French Hospital reported with atypical pneumonia  Early March – Hong Kong, SAR China Official report of 77 medical staff from Hospital reported with atypical pneumonia`, WHO teams arrive Hong Kong and Hanoi, and with governments advise on investigation and containment activities
  • 8. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 8 Global Alert: Severe Acute Respiratory Syndrome (SARS)  12 March: First global alert – describing atypical pneumonia in Viet Nam and Hong Kong  14 March – Four persons Ontario, three persons in Singapore, with severe atypical pneumonia fitting description of 12 March alert reported to WHO  15 March – Medical doctor with atypical pneumonia fitting description of 12 March reported by Ministry of Health, Singapore on return flight from New York
  • 9. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 9 Global Alert, 15 March 2003 1) Atypical pneumonia with rapid progression to respiratory failure 2) Health workers appeared to be at greatest risk 3) Unidentified cause, presumed to be an infectious agent 4) Antibiotics and antivirals did not appear effective 5) Spreading internationally within Asia and to Europe and North America
  • 10. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 10  15 March: Second global alert • Case definition provided • Name (SARS) announced • Advice given to international travellers to raise awareness  26 March Evidence accumulating that persons with SARS continued to travel from areas with local transmission, and that adjacent passengers were at small, but non-quantified risk  27 March Guidance provided to airlines and areas with local transmission to screen passengers leaving in order to decrease risk of international travel by persons with SARS Global Alert: Severe Acute Respiratory Syndrome (SARS)
  • 11. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 11 Global Alert: Severe Acute Respiratory Syndrome (SARS)  1 April: Evidence accumulating from exported cases that three criteria were potentially increasing international spread: – magnitude of outbreak and number of new cases each day – pattern of local transmission – exportation of probable cases  2 April to present: Guidance provided to general public to postpone non-essential travel to areas with local transmission that met above criteria
  • 12. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 12 SARS: cumulative number of probable cases worldwide as of 12 June 2003 – Total: 8 445 cases, 790 deaths China (5328) Singapore (206) Hong Kong (1755) Viet Nam (63) Europe: 10 countries (38) Thailand (9) Brazil (3) Malaysia (5) South Africa (1) Canada (238) USA (70) Outbreaks before 15 March global alert Colombia (1) Kuwait (1) South Africa (1) Korea Rep. (3) Macao (1) Philippines (14) Indonesia (2) Mongolia (9) India (3) Australia (5) New Zealand (1) Taiwan (688) Outbreaks after 15 March global alert Mongolia (9) Russian Fed. (1)
  • 13. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 13 Probable cases of SARS by date of onset, Hanoi: n = 62 1 February – 12 June 2003 0 1 2 3 4 5 6 7 8 9 10 1 Feb. 11 Feb. 21 Feb. 3 March 13 March 23 March 2 April 12 April 22 April 2 May 12 June Number of cases
  • 14. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 14 Probable cases of SARS by date of onset, Singapore: n = 206 1 February – 12 June 2003 Source: Ministry of Health, Singapore, WHO 0 2 4 6 8 10 12 14 1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 29 May Number of cases 12 Jun.
  • 15. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 15 Probable cases of SARS by date of onset, Canada: n = 227* 1 February – 12 June 2003 Number of cases 0 1 2 3 4 5 6 7 8 9 10 1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 -Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 1 Jun. 12 Jun. * As of 12 June 2003, 11 additional probable cases of SARS have been reported from Canada for whom no dates of onset are available. Source: Health Canada
  • 16. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 16 Probable cases of SARS by date of onset, Taiwan: n = 688 1 February – 12 June 2003 Number of cases 0 5 10 15 20 25 30 1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 1 Jun. 12 Jun.
  • 17. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 17 Probable cases of SARS by date of onset, Beijing: n = 2,522 0 50 100 150 200 250 300 350 30-Mar-03 13-Apr-03 27-Apr-03 11-May-03 25-May-03 8-Jun-03 date of report number of cases
  • 18. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 18 156 close contacts of HCW and patients Index case from Guangdong Hospital 2 Hong Kong 4 HCW + 2 Hospital 3 Hong Kong 3 HCW Hospital 1 Hong Kong 99 HCW Canada 12 HCW + 4 Hotel M Hong Kong Ireland USA New York Singapore 34 HCW + 37 Viet Nam 37 HCW + ? Bangkok HCW 4 other Hong Kong hospitals 28 HCW Hospital 4 Hong Kong B I K F G E D C J H A SARS: chain of transmission among guests at Hotel Metropole, Hong Kong, 21 February Germany HCW + 2 As of 26 March, 249 cases have been traced to the A case Source: WHO/CDC
  • 19. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 19 Airport screening and health information, Hong Kong, SARS, 2003
  • 20. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 20 Probable cases of SARS by date of onset, Hong Kong: n = 1 753, as of 9 June 2003 Number of cases 0 1 Feb. 13 Feb. 25 Feb. 9 Mar. 21 Mar. 2 Apr. 14 Apr. 26 Apr. 8 May 20 May 1 Jun. 9 Jun. 0 20 40 60 80 100 120
  • 21. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 21 SARS and the economy: impact on global travel, Hong Kong
  • 22. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 22 SARS and the economy: impact on global travel, Singapore
  • 23. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 23 The cost of SARS: Initial estimates, Asian Development Bank
  • 24. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 24 1) Atypical pneumonia with rapid progression to respiratory failure: – Case fatality rate by age group: – 85% full recovery – Incubation period: 3–10 days 2) Health workers appeared to be at greatest risk – Health workers remain primary risk group in second generation – Others at risk include family members of index cases and health workers, and their contacts – Majority of transmission has been close personal contact; in Hong Kong environmental factors caused localized transmission < 1% < 24 years old 6% 25–44 years old 15% 45–64 years old > 50% > 65 years old SARS: what more we know 3 months later
  • 25. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 25 SARS: what more we know 3 months later 3) Unidentified cause, presumed to be an infectious agents – Aetiological agent: Coronavirus, hypothesized to be of animal origin – PCR and various antibody tests developed and being used in epidemiological studies, but PCR lacks sufficient sensitivity as diagnostic tool 4) Antibiotics and antivirals did not appear effective – Studies under way to definitively provide information on effectiveness of antivirals alone or in combination with steroids, and on use of hyperimmune serum in persons with severe disease – Case detection, isolation, infection control and contact tracing are effective means of containing outbreaks – Meeting 30 April at NIH to examine priorities in drugs and vaccine developments
  • 26. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 26 SARS: what more we know 3 months later 5) Spreading internationally within Asia and to Europe and North America – Only 1 major outbreak occurred after 15 March despite initial exported cases to a total of 32 countries – Symptomatic persons with SARS no longer travelling internationally – International spread occurring the in small number of persons who are in incubation period – Since 15 March, 27 persons on 4 of 32 international flights carrying symptomatic persons with SARS appear to have been infected (1 flight alone on 15 March has accounted for 22 of these 27 cases), and these occurred before 23 March
  • 27. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 27 SARS: what we are learning  In the world today an infectious disease in one country is a threat to all: infectious diseases do not respect international borders  Information and travel guidance can contain the international spread of an infectious disease  Experts in laboratory, epidemiology and patient care can work together for the public health good despite heavy pressure to publish academically  Emerging infectious disease outbreaks often have an unnecessary negative economic impact on tourism, travel and trade  Infectious disease outbreaks reveal weaknesses in public health infrastructure  Emerging infections can be contained with high level government commitment and international collaboration if necessary
  • 28. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 28 SARS: what Hong Kong has contributed to the global effort  Reporting: open and transparent reporting of H5N1 on 19 February that led to intensified global surveillance for respiratory disease  Reporting: open and transparent reporting in early March of health worker infection, leading to global alert on 12 March  Information: new cases and deaths reported regularly to WHO  Science: coronavirus first isolated and identified, early PCR and antibody tests developed, environmental factors involved in transmission identified, studies on animal reservoir in collaboration with Guandong scientists conducted  Outbreak Control: prompt reaction once outbreak had been identified, with effective case identification, contact tracing, isolation/infection control, surveillance and quarantine despite environmental transmission at Amoy Gardens  Patient management: controlled studies on antivrial drugs alone and in combination with steroids, convalescent serum for treatment
  • 29. WHO COMMUNICABLE DISEASES • SARS, 15 June 2003 29 SARS: what Hong Kong will contribute to the global effort over coming months  Continued case identification through surveillance: – necessary to determine whether infection is endemic and seasonal, or whether it has disappeared from human populations  Continued collaboration with China, particularly Guangdong Province in studies to identify animal reservoir and risk factors for transmission to humans – necessary to manage the risk and prevent future outbreaks  Continued participation in major WHO networks of global surveillance for influenza and other infectious diseases – identify next major emergence of new influenza strain or other infection of international importance